In clinical trials, DGAT1 inhibitors have not shown precise anti-obesity and anti-diabetic effects, because the drug doses are limited, at least in part, due to lack of an adequate therapeutic window between the efficacy dose and the dose causing the GI adverse effects [32–34]. Here, DGAT1 is linked to obesity due to melanocortin 4 receptor deficiency.